

GLOBAL & REGIONAL DAILY

HIGHLIGHTS

December 1, 2020

Global Markets

Global equity markets kicked off the new month in a positive tone as the prospect of an effective Covid-19 vaccine supports optimism for a swift global economic recovery. Moderna announced that it has requested authorization of its vaccine in the US and Europe after results confirmed a 94.1% efficacy rate, becoming possibly the second vaccine to be available for US use by year-end, alongside the Pfizer and BioNTech vaccine that is already under regulatory review. Data pointing to an acceleration in China's post-pandemic economic recovery and expectations for further stimulus by both the ECB and the Fed, also favoured risk sentiment. The USD remained under pressure, with the DXY index hovering close to y-day's 2 ½ year lows. Today's focus is on the Fed Chair's testimony on the CARES Act before the Senate Banking Committee.

Greece

The IMF released yesterday its statement in the context of the second post-programme monitoring discussion, where it argues that GDP is expected to contract sharply in 2020, while the subsequent recovery could be protracted. Public debt remains sustainable over the medium-term with the pandemic-induced rise in debt vulnerabilities largely mitigated by a sizable cash buffer and Next Generation EU funds. However, downside risks stem primarily from the prolongation of the pandemic and a significant deterioration of bank balance sheets. The IMF commends Greece for the recent progress in reforms and reiterates its key policy recommendations including fiscal structural reforms, strengthening bank balance sheet and accelerating selected structural reforms.

CESEE

A plethora of hard data was released yesterday, pointing to a mixed picture for Serbia. Q3 GDP growth came in at -1.4%YoY (vs the flash estimate of -1.3%YoY earlier in November) and +7.4%QoQ compared to -6.3%YoY and -9.3%QoQ in Q2. However, the Labor Force Survey (LFS)-based unemployment rate rose to 9.0% in Q3 after hitting a record low of 7.3% in the previous quarter. October's high frequency data releases imply some loss of momentum; retail sales in real terms eased to 6.3%YoY from 7.7%YoY in September and industrial output decelerated to 1.9%YoY from 4.6%YoY in the previous month. Meanwhile, on Friday, the S&P affirmed Bulgaria's long- and short-term foreign and local currency credit rating at BBB/A-2, keeping the outlook stable and forecasting a -4.5% GDP contraction for 2020.

Contributing Authors

Paraskevi Petropoulou
Senior Economist
ppetropoulou@eurobank.gr

Anna Dimitriadou
Economic Analyst
andimitriadou@eurobank.gr

Maria Kasola
Economic Analyst
mkasola@eurobank.gr

GLOBAL MARKETS

Stock markets




	Last	ΔD	ΔYTD
S&P 500	3621.63	-0.46%	12.1%
Nikkei 225	26787.54	1.3%	13.2%
STOXX 600	389.36	-1.0%	-6.4%

FOREX

	Last	ΔD	ΔYTD
EUR/USD	1.1969	0.4%	6.7%
GBP/USD	1.3386	0.5%	1.0%
USD/JPY	104.31	0.0%	4.1%

Government Bonds


(yields)	Last	ΔDbps	ΔYTD bps
UST - 10yr	0.84	0	-108
Bund-10yr	-0.58	-1	-40
JGB - 10yr	0.02	-1	3



GREECE

Government Bonds

(yields)	Last	ΔDbps	ΔYTDbps
5Y Bond	0.02	0	-47
10Y Bond	0.63	0	-80



ATHENS GENERAL INDEX



EMERGING MARKETS

Stock markets

	Last	ΔD	ΔYTD
SOFIX	423.33	-0.6%	-25.5%
BELEX	713.57	-0.3%	-1099.2%
XU100	1296.94	1.0%	1334.4%


FOREX

	Last	ΔD	ΔYTD
EUR/PLN	4.4815	-0.1%	-5.1%
EUR/RSD	117.566	0.1%	0.1%
USD/TRY	7.8875	-0.8%	-24.6%

Government Bonds

	Last	ΔDbps	ΔYTD bps
TR 10Y yield	5.94	19	-19
BG 8Y yield	Invalid Security		
PL 10Y yield	1.23		


MSCI EM EQUITY INDEX



MSCI EM CURRENCY INDEX





JPEMBI PLUS INDEX




COMMODITIES

	Last	ΔD	ΔYTD
GOLD	1793	0.9%	18.2%
BRENT CRUDE	48	-0.6%	-27.9%
LME X	3379	0.7%	18.8%



LONDON METAL EXCHANGE INDEX



Research Team



Dr. Tasos Anastasatos | Group Chief Economist
tanastasatos@eurobank.gr | + 30 214 40 59 706



Anna Dimitriadou
Economic Analyst
andimitriadou@eurobank.gr
+ 30 210 37 18 793



Ioannis Gkionis
Senior Economist
igkionis@eurobank.gr
+ 30 214 40 59 707



Dr. Stylianos Gogos
Economic Analyst
sgogos@eurobank.gr
+ 30 210 37 18 733



Maria Kasola
Economic Analyst
mkasola@eurobank.gr
+ 30 210 33 18 708



Olga Kosma
Research Economist
okosma@eurobank.gr
+ 30 210 37 18 728



Paraskevi Petropoulou
Senior Economist
ppetropoulou@eurobank.gr
+ 30 210 37 18 991



Dr. Theodoros Rapanos
Economic Analyst
v-trapanos@eurobank.gr
+ 30 214 40 59 711



Dr. Theodoros Stamatou
Senior Economist
tstamatou@eurobank.gr
+ 30 214 40 59 708



Elia Tsiampaou
Economic Analyst
etsiampaou@eurobank.gr
+ 30 214 40 59 712

Περισσότερες εκδόσεις μας διαθέσιμες στην ηλεκτρονική διεύθυνση που ακολουθεί: <https://www.eurobank.gr/en/group/economic-research>
Εγγραφείτε ηλεκτρονικά, σε: <https://www.eurobank.gr/el/omilos/oikonomikes-analuseis/forma-ekdilosis-endiaterontos>
Ακολουθήστε μας στο twitter: https://twitter.com/Eurobank_Group
Ακολουθήστε μας στο LinkedIn: <https://www.linkedin.com/company/eurobank>

DISCLAIMER

This report has been issued by Eurobank S.A. ("Eurobank") and may not be reproduced in any manner or provided to any other person. Each person that receives a copy by acceptance thereof represents and agrees that it will not distribute or provide it to any other person. This report is not an offer to buy or sell or a solicitation of an offer to buy or sell the securities mentioned herein. Eurobank and others associated with it may have positions in, and may effect transactions in securities of companies mentioned herein and may also perform or seek to perform investment banking services for those companies. The investments discussed in this report may be unsuitable for investors, depending on the specific investment objectives and financial position. The information contained herein is for informative purposes only and has been obtained from sources believed to be reliable but it has not been verified by Eurobank. The opinions expressed herein may not necessarily coincide with those of any member of Eurobank. No representation or warranty (express or implied) is made as to the accuracy, completeness, correctness, timeliness or fairness of the information or opinions herein, all of which are subject to change without notice. No responsibility or liability whatsoever or howsoever arising is accepted in relation to the contents hereof by Eurobank or any of its directors, officers or employees. Any articles, studies, comments etc. reflect solely the views of their author. Any unsigned notes are deemed to have been produced by the editorial team. Any articles, studies, comments etc. that are signed by members of the editorial team express the personal views of their author.

